379 related articles for article (PubMed ID: 22164924)
41. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
[TBL] [Abstract][Full Text] [Related]
42. Prospective assessment of microsatellite instability in gastrointestinal neoplasia in Ashkenazi and non-Ashkenazi Jews.
Strul H; Liberman E; Kariv R; Gartner M; Kazanov D; Keidar A; Carmeli Y; Degani Y; Halpern Z; Arber N
J Med; 2003; 34(1-6):139-48. PubMed ID: 17682319
[TBL] [Abstract][Full Text] [Related]
43. Systematic immunohistochemical screening for Lynch syndrome in colorectal cancer: a single centre experience of 486 patients.
Zumstein V; Vinzens F; Zettl A; Heinimann K; Koeberle D; von Flüe M; Bolli M
Swiss Med Wkly; 2016; 146():w14315. PubMed ID: 27152634
[TBL] [Abstract][Full Text] [Related]
44. A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours.
Schofield L; Grieu F; Goldblatt J; Amanuel B; Iacopetta B
Fam Cancer; 2012 Mar; 11(1):1-6. PubMed ID: 22120844
[TBL] [Abstract][Full Text] [Related]
45. Success of referral to genetic counseling after positive lynch syndrome screening test.
Irons RF; Contino KM; Horte JJ; Levin B; Mattie KD; Wight M; Kwiatt ME; Behling KC; Edmonston TB; McClane SJ
Int J Colorectal Dis; 2017 Sep; 32(9):1345-1348. PubMed ID: 28664346
[TBL] [Abstract][Full Text] [Related]
46. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
[TBL] [Abstract][Full Text] [Related]
47. [Molecular cancer disposition diagnosis exemplified by colorectal carcinoma. What is the contribution of pathology?].
Rüschoff J; Dietmaier W; Bocker T; Wallinger S; Kullmann F; Beham A; Hofstädter F
Pathologe; 1998 Jul; 19(4):269-78. PubMed ID: 9746911
[TBL] [Abstract][Full Text] [Related]
48. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.
Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK
Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164
[TBL] [Abstract][Full Text] [Related]
49. Performance of tumor testing for Lynch syndrome identification in patients with colorectal cancer: A retrospective single-center study.
Signoroni S; Tibiletti MG; Ricci MT; Milione M; Perrone F; Pensotti V; Chiaravalli AM; Carnevali I; Morabito A; Bertario L; Vitellaro M
Tumori; 2019 Feb; 105(1):76-83. PubMed ID: 30117378
[TBL] [Abstract][Full Text] [Related]
50. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.
Garg K; Leitao MM; Kauff ND; Hansen J; Kosarin K; Shia J; Soslow RA
Am J Surg Pathol; 2009 Jun; 33(6):925-33. PubMed ID: 19238076
[TBL] [Abstract][Full Text] [Related]
51. Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan.
Chen YE; Kao SS; Chung RH
PLoS One; 2016; 11(8):e0160599. PubMed ID: 27482709
[TBL] [Abstract][Full Text] [Related]
52. Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome.
Ponti G; Castellsagué E; Ruini C; Percesepe A; Tomasi A
Clin Genet; 2015 Jun; 87(6):507-16. PubMed ID: 25345868
[TBL] [Abstract][Full Text] [Related]
53. Review article: The Lynch syndrome (hereditary nonpolyposis colorectal cancer).
Vasen HF
Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():113-26. PubMed ID: 18081655
[TBL] [Abstract][Full Text] [Related]
54. Genetic susceptibility to non-polyposis colorectal cancer.
Lynch HT; de la Chapelle A
J Med Genet; 1999 Nov; 36(11):801-18. PubMed ID: 10544223
[TBL] [Abstract][Full Text] [Related]
55. Application of molecular diagnostics for the detection of Lynch syndrome.
Pino MS; Chung DC
Expert Rev Mol Diagn; 2010 Jul; 10(5):651-65. PubMed ID: 20629513
[TBL] [Abstract][Full Text] [Related]
56. Spectrum of MLH1 and MSH2 mutations in Chilean families with suspected Lynch syndrome.
Alvarez K; Hurtado C; Hevia MA; Wielandt AM; de la Fuente M; Church J; Carvallo P; López-Köstner F
Dis Colon Rectum; 2010 Apr; 53(4):450-9. PubMed ID: 20305446
[TBL] [Abstract][Full Text] [Related]
57. Colorectal cancer due to deficiency in DNA mismatch repair function: a review.
Bellizzi AM; Frankel WL
Adv Anat Pathol; 2009 Nov; 16(6):405-17. PubMed ID: 19851131
[TBL] [Abstract][Full Text] [Related]
58. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
[TBL] [Abstract][Full Text] [Related]
59. Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?
Maccaroni E; Bracci R; Giampieri R; Bianchi F; Belvederesi L; Brugiati C; Pagliaretta S; Del Prete M; Scartozzi M; Cascinu S
Oncotarget; 2015 Nov; 6(36):38737-48. PubMed ID: 26485756
[TBL] [Abstract][Full Text] [Related]
60. Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.
Baris HN; Barnes-Kedar I; Toledano H; Halpern M; Hershkovitz D; Lossos A; Lerer I; Peretz T; Kariv R; Cohen S; Half EE; Magal N; Drasinover V; Wimmer K; Goldberg Y; Bercovich D; Levi Z
Pediatr Blood Cancer; 2016 Mar; 63(3):418-27. PubMed ID: 26544533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
